OBJECTIVE: To describe the epidemiology of ventilator-associated pneumonia (VAP) in community hospitals. DESIGN AND SETTING: Prospective study in 31 community hospitals from 2007 to 2011. METHODS: VAP surveillance was performed by infection preventionists using the National Healthcare Safety Network protocol. VAP incidence was reported as number of events per 1,000 ventilator-days. We categorized hospitals into small (<30,000 patient-days/year), medium (30,000-60,000 patient-days/year), and large (>60,000 patient-days/year) groups and compared VAP incidence by hospital size. RESULTS: he median VAP incidence was 1.4 (interquartile range, 0.4-2.4), and ventilator utilization ratio (VUR) was 0.33 (0.25-0.47). VAP incidence was higher in small hospitals (2.1) than medium (0.85) or large (0.69) hospitals ([Formula: see text]) despite a lower VUR in small hospitals (0.29 vs 0.31 vs 0.44, respectively; [Formula: see text]). The median age of 247 VAP cases was 64 (53-73); 136 (55.1%) were female; 142 (57.5%) were Caucasian; 170 (68.8%) were admitted from home. The length of stay and duration of ventilation were 26 (14-42) and 12 (4-21) days, respectively. The pre- and postinfection hospital stays were 8 (3-13) days and 14 (8-30) days, respectively. Data on outcomes were available in 214 cases (86.6%), and 75 (35.0%) cases died during hospitalization. The top 3 pathogens were methicillin-resistant Staphylococcus aureus (MRSA; [Formula: see text], 27.9%), Pseudomonas species ([Formula: see text], 16.3%), and Klebsiella species ([Formula: see text], 13.3%). CONCLUSIONS: VAP incidence was inversely associated with size of hospital. VAP in community hospitals was frequently caused by MRSA. Importantly, predictors of VAP incidence in tertiary care hospitals such as VUR may not be predictive in community hospitals with few ventilated patients.
OBJECTIVE: To describe the epidemiology of ventilator-associated pneumonia (VAP) in community hospitals. DESIGN AND SETTING: Prospective study in 31 community hospitals from 2007 to 2011. METHODS: VAP surveillance was performed by infection preventionists using the National Healthcare Safety Network protocol. VAP incidence was reported as number of events per 1,000 ventilator-days. We categorized hospitals into small (<30,000 patient-days/year), medium (30,000-60,000 patient-days/year), and large (>60,000 patient-days/year) groups and compared VAP incidence by hospital size. RESULTS: he median VAP incidence was 1.4 (interquartile range, 0.4-2.4), and ventilator utilization ratio (VUR) was 0.33 (0.25-0.47). VAP incidence was higher in small hospitals (2.1) than medium (0.85) or large (0.69) hospitals ([Formula: see text]) despite a lower VUR in small hospitals (0.29 vs 0.31 vs 0.44, respectively; [Formula: see text]). The median age of 247 VAP cases was 64 (53-73); 136 (55.1%) were female; 142 (57.5%) were Caucasian; 170 (68.8%) were admitted from home. The length of stay and duration of ventilation were 26 (14-42) and 12 (4-21) days, respectively. The pre- and postinfection hospital stays were 8 (3-13) days and 14 (8-30) days, respectively. Data on outcomes were available in 214 cases (86.6%), and 75 (35.0%) cases died during hospitalization. The top 3 pathogens were methicillin-resistant Staphylococcus aureus (MRSA; [Formula: see text], 27.9%), Pseudomonas species ([Formula: see text], 16.3%), and Klebsiella species ([Formula: see text], 13.3%). CONCLUSIONS: VAP incidence was inversely associated with size of hospital. VAP in community hospitals was frequently caused by MRSA. Importantly, predictors of VAP incidence in tertiary care hospitals such as VUR may not be predictive in community hospitals with few ventilated patients.
Authors: Jeremy M Kahn; Christopher H Goss; Patrick J Heagerty; Andrew A Kramer; Chelsea R O'Brien; Gordon D Rubenfeld Journal: N Engl J Med Date: 2006-07-06 Impact factor: 91.245
Authors: D J Cook; S D Walter; R J Cook; L E Griffith; G H Guyatt; D Leasa; R Z Jaeschke; C Brun-Buisson Journal: Ann Intern Med Date: 1998-09-15 Impact factor: 25.391
Authors: Justin L Ranes; Steven M Gordon; Pam Chen; Cynthia Fatica; Jeffrey Hammel; Jeffrey P Gonzales; Alejandro C Arroliga Journal: Am J Med Date: 2006-10 Impact factor: 4.965
Authors: Eva Tejerina; Fernando Frutos-Vivar; Marcos I Restrepo; Antonio Anzueto; Fekri Abroug; Fernando Palizas; Marco González; Gabriel D'Empaire; Carlos Apezteguía; Andrés Esteban Journal: J Crit Care Date: 2006-03 Impact factor: 3.425
Authors: Deverick J Anderson; Matthew G Hartwig; Theodore Pappas; Daniel J Sexton; Zeina A Kanafani; Grace Auten; Keith S Kaye Journal: Ann Surg Date: 2008-02 Impact factor: 12.969
Authors: Steven Y C Tong; Joshua S Davis; Emily Eichenberger; Thomas L Holland; Vance G Fowler Journal: Clin Microbiol Rev Date: 2015-07 Impact factor: 26.132
Authors: Nguyen Thi Khanh Nhu; Nguyen Phu Huong Lan; James I Campbell; Christopher M Parry; Corinne Thompson; Ha Thanh Tuyen; Nguyen Van Minh Hoang; Pham Thi Thanh Tam; Vien Minh Le; Tran Vu Thieu Nga; Tran Do Hoang Nhu; Pham Van Minh; Nguyen Thi Thu Nga; Cao Thu Thuy; Le Thi Dung; Nguyen Thi Thu Yen; Nguyen Van Hao; Huynh Thi Loan; Lam Minh Yen; Ho Dang Trung Nghia; Tran Tinh Hien; Louise Thwaites; Guy Thwaites; Nguyen Van Vinh Chau; Stephen Baker Journal: J Med Microbiol Date: 2014-07-18 Impact factor: 2.472
Authors: Antonio Eduardo P Pesaro; Marcelo Katz; Jason N Katz; Carmen Sílvia Valente Barbas; Marcia R Makdisse; Alessandra G Correa; Marcelo Franken; Carolina Pereira; Carlos V Serrano; Renato D Lopes Journal: PLoS One Date: 2016-03-15 Impact factor: 3.240